2682results about "Nervous system cells" patented technology

The invention relates to the technical field of cytology, in particular to a grass carp brain astrocyte line and application thereof, the grass carp brain astrocyte line is preserved in China Center for Type Culture Collection on May 7, 2025, and the preservation number of the grass carp brain astrocyte line is CCTCC NO: C2025149. The grass carp brain astroglia cell line provided by the invention has the capability of efficiently proliferating GCRV-II, and the virus titer of the GCRV-II replicated in the cell line at least can reach 1.38 * 10 < 8 > pfu / mL or above; after the GCRV-II is blindly passed for 5 generations in a grass carp astroglia cell line, the grass carp can still have typical bleeding symptoms and death due to the virus. And the exogenous plasmid transfected grass carp brain astroglia cell line has similar transfection efficiency to commercial grass carp kidney cells. Therefore, the invention lays an important foundation for deep research of pathogenic mechanism of GCRV-II, vaccine preparation, antiviral drug screening and prevention and control of grass carp viral hemorrhagic disease.

The invention provides a cognitive function in-vitro simulation method based on a microelectrode array (MEA) and brain organs and application of the cognitive function in-vitro simulation method, and belongs to the crossing field of brain organ in-vitro model construction, neural engineering, brain-like intelligence and the like. In an in-vitro environment, external signal (such as sound) information is converted into electrical stimulation input capable of being perceived by brain organs in an MEA electrical stimulation mode, so that the brain organs gradually learn and identify external signals in repeated electrical stimulation; after elution stimulation for a period of time, the reduction condition of recognition accuracy is observed, namely, the important memory and forgetting process in the cognitive function is simulated. According to the method, the electrophysiological response and the biological mechanism change of the brain organs under external electrical stimulation can be quantitatively evaluated, and a new possibility is provided for exploring the advanced cognitive function by utilizing the brain organs.

A device for modelling physiological and pathophysiological states of the brain is provided. The device comprises a hydrogel with micropattern channels having a length, width and depth. The micropattern channels comprise cells selected from the group consisting of neurons, astrocytes, microglia, oligodendrocytes, neuronal organoids, cancer cells, cancer spheroids, brain tumoral cells and combinations thereof.

The invention discloses application of MIGA2 as a therapeutic target in a medicine for preventing and treating Alzheimer's disease, and belongs to the technical field of biological medicine. The MIGA2 gene is used as a therapeutic target to be applied to development, screening or preparation of drugs for preventing and treating Alzheimer's disease. After an MIGA2 overexpression plasmid is adopted to transfect an Alzheimer's disease cell model, it is found that autophagy flow in cells can be promoted and accumulation of related toxic proteins can be reduced, it is proved that MIGA2 has the neuroprotective effect on the Alzheimer's disease, and a new way and exploration direction are provided for treatment of the Alzheimer's disease.

The invention relates to a cochlea spiral neuron in-vitro organ as well as a construction method and application thereof, and provides a method for obtaining a mature inner ear neuron by utilizing human pluripotent stem cell differentiation in vitro and further constructing an inner ear neuron in-vitro organ on the basis of the mature inner ear neuron. The internal ear neuron in-vitro organoid function stage obtained by the method and the application thereof are also provided.

A brain organoid containing optic vesicles generated based on H9 induction and an eye-brain fusion culture method thereof are provided. H9 embryonic stem cell induction is used to generate a brain organoid containing optic vesicles with primitive visual field. Based on an established optic vesicle brain organoid culture system, microscopic imaging is combined with specific marker antibodies related to early retinal development and photoreceptor cell maturation to structurally and functionally identify the brain organoid containing optic vesicles.

The invention discloses a multi-brain organ electron complex as well as a construction method and application thereof. The multi-brain organ electronic complex comprises a microelectrode array and a fusion organ attached to the surface of a chip electrode of the microelectrode array through a PDMS film, and the fusion organ can grow for more than or equal to 120 days through culture. The PDMS film is attached to the surface of the MEA chip electrode, so that the stability of combination of the MEA chip electrode and the organoid is remarkably enhanced, the construction efficiency of a multi-brain organoid electron complex is improved, and the continuity of neural signal detection is improved; a high-performance model platform is provided for multi-brain organ research, and the method has a wide application prospect.

Methods of treating a nerve injury are disclosed. The methods include administering to a target site of the nerve injury a thermally stable preparation having a purified amphiphilic peptide in an aqueous biocompatible solution, being configured to self-assemble into a hydrogel, and administering to the target site a buffer having an effective amount of an ionic salt and a biological buffering agent to form the hydrogel. The methods include administering to the target site a biological material suspension in an amount effective to treat the nerve injury. The methods include administering to the target site an anti-scarring agent in an amount effective to treat the nerve injury. The target site is associated with central nervous system tissue or peripheral nervous system tissue. The nerve injury includes spinal cord injury and peripheral nerve injury.

The invention discloses an application of a CD73 + NK cell in preparation of a medicine for preventing or treating Parkinson's disease. The applicant discovers that the CD73 + NK cell can prevent dopaminergic neuron loss and glial inflammation response of the MPP + induced VM cell in the experimental process. However, TGF-beta1 and IL-10 secreted by the CD73 + NK cells do not significantly prevent loss of dopaminergic neurons induced by MPP + in cross-pore co-culture of the CD73 + NK cells and VM neurons. Therefore, the CD73 + NK cells are proved to protect dopaminergic neurons from the influence of MPP + neurotoxicity through an intercellular contact mechanism, namely CD73-SIRPA interaction.

The invention relates to a cell collection method capable of simultaneously collecting three cells in a co-culture model, and belongs to the technical field of biology. The invention provides a cell collection method capable of simultaneously collecting three cells in a co-culture model, and the cell collection method comprises the following steps: after a three-cell co-culture model is constructed, taking out a Transwell chamber, retaining cells in the lower chamber, and collecting the cells in the lower chamber; respectively digesting the cells on the two sides of the Transwell cell membrane by using a trypsin solution with the concentration of 0.5 g / 100mL so as to respectively collect the cells on the two sides of the Transwell cell membrane. According to the cell collection method disclosed by the invention, the three cells in the three-cell co-culture model are simultaneously collected in a manner of digesting the cells on the two sides of the Transwell membrane step by step by using pancreatin, so that not only is the cell and consumable cost saved, but also the experimental synchronism of the three cells is ensured, and convenience is provided for optimizing the experimental process.

Provided are a method and the like for efficiently screening for a candidate substance for a starting material that suppresses hexanal odor. The screening method according to the present invention comprises the steps of: adding a test substance and hexanal to a specific olfactory receptor polypeptide; a step for measuring the response of the olfactory receptor polypeptide to hexanal; and identifying, on the basis of the measured response, a test substance that inhibits the response of the olfactory receptor polypeptide as a candidate substance for a raw material that inhibits hexanal odor.

The present disclosure relates to a method for producing an inner ear organoid with improved differentiation efficiency of hair cells. The inventors of the present disclosure have confirmed that when retinoic acid is treated at the stage of formation of the lamina propria during the production of an inner ear organoid, the differentiation potential of hair cells is excellent. Therefore, it is expected that the inner ear organoid produced according to the production method of the present disclosure can be advantageously utilized in hearing loss disease modeling, drug screening and regenerative medicine.

The invention provides a method for constructing a chronic unpredictable negative stress model, the chronic unpredictable negative stress model and application of the chronic unpredictable negative stress model in mental disease research, and belongs to the field of brain organ in-vitro model construction. Through dual verification of a microelectrode array and single cell sequencing, an in-vitro brain organ model capable of simulating chronic unpredictable negative stress core characteristics is successfully constructed, and a potential neural network function reconstruction mechanism and a cell molecule basis of the in-vitro brain organ model are disclosed. The comprehensive research normal form breaks through the limitation of a traditional single technology platform, and an accurate and efficient innovative research platform highly related to human is provided for pathogenesis research of mental diseases, especially chronic stress related diseases such as depression and anxiety and development of novel treatment strategies.

The invention discloses a bone organ chip loaded with a microelectrode array and a use method, and relates to the technical field of organ chips, the bone organ chip is made of a polydimethylsiloxane material, and the bone organ chip comprises a three-layer structure: a top layer, a middle layer and a bottom layer; the middle layer comprises two blood vessel micro-channels, two osteoblast micro-channels and a neuron micro-channel, the channels are separated through columns and micro-columns, and cell interaction in a bone micro-environment is simulated; a microelectrode array is arranged on the top layer and is used for monitoring electrical activity of neurons in real time; the bottom layer is provided with a pneumatic valve which can control opening and closing of the micro-channel. According to the invention, nerve and blood vessel channels are introduced, a nerve-blood vessel-immunoregulation bone microenvironment is constructed, physiological processes such as osteogenesis-blood vessel formation coupling and the like are embodied, intervals of different sizes can enhance intercellular crosstalk and allow blood vessels and neuron axons to selectively pass through, so that the chip can simulate a complex microenvironment of bone tissues, and the microenvironment of the bone tissues can be simulated; and an efficient and accurate in-vitro model is provided for bone disease mechanism research and drug development.

The invention relates to the technical field of biology. The invention provides a grass carp brain cell line sensitive to grass carp reovirus type II, which is preserved in China Center for Type Culture Collection on October 19, 2024, and the preservation number is CCTCC NO: C2024101. The constructed grass carp brain cell line shows remarkable stability, and stable passage is successfully achieved for 60 times. And when GCRV-II is inoculated, an atypical cytopathic effect can be presented. In addition, the grass carp brain cell line has the capability of efficiently replicating GCRV-II, and even if blind passage is carried out for three generations, generated cytotoxicity can still cause morbidity and death of the grass carp. Therefore, a stable foundation is built for deeply exploring the pathogenic mechanism of the GCRV-II, developing vaccine development, screening antiviral drugs and the like, research in related fields is promoted to further progress, and a key cell model and a research basis are provided for development of related research and prevention and control strategies of the grass carp reovirus.

The invention provides a culture system for simulating neutrophile granulocyte extracellular trap net intervention oligodendrocyte in vitro, and belongs to the technical field of cell and function detection. The invention establishes a stable and repeatable research system by screening and determining the optimal condition for in-vitro co-culture of the neutrophil extracellular trap net and the oligodendroglia. Based on the condition, the experiment can observe the obvious change of the oligodendroglia after the intervention, and the result shows that the condition can accurately simulate the endoplasmic reticulum stress regulation effect of the neutrophile granulocyte extracellular trap net on the oligodendroglia, thereby providing a necessary experimental basis for the subsequent mechanism research.

The invention relates to a retina nerve and blood vessel unit in-vitro three-culture model and a preparation method thereof, and belongs to the technical field of biology. The invention provides an in-vitro three-culture model of a retina nerve and blood vessel unit. The in-vitro three-culture model is obtained by carrying out in-vitro Transwell indirect co-culture on retina microvascular endothelial cells, retina ganglion cells and retina Muller cells. The in-vitro three-culture model of the retina nerve and blood vessel unit is based on a three-cell indirect co-culture method, retina microvascular endothelial cells, retina ganglion cells and retina Muller cells are simultaneously incorporated by utilizing Transwell, and the three cells are in indirect contact. The in-vitro three-culture model of the retina nerve and blood vessel unit can be used for more objectively simulating pathophysiological states of various cells of the retina nerve and blood vessel unit, so that common pathophysiological changes of mutual dependence and interaction of the three cells under in-vitro conditions can be observed.

An object of the present invention is to provide a cell population suitable for transplant of retinal tissue and a method of production thereof. The present invention provides a cell population for transplant, comprising retinal cells with a modified bipolar cell-regulating gene and a method of production thereof.

The invention provides an application of a human retina organ in preparation of a medicament for treating traumatic optic neuropathy. According to the invention, the induced and differentiated human retina-like organ is applied to the optic nerve injury area, and the eye and brain nerve connection can be functionally reconstructed, so that the damaged visual function is recovered.

The present invention relates to a method of transiently inducing aging in stem cells or somatic cells derived from induced pluripotent stem cells (iPSCs) by forward programming, the method comprising introducing one or more aging-inducing factors into the cell or exposing the cell to one or more exogenous aging-inducing factors for a period of time, the one or more aging-inducing factors are then removed or reduced, such as before or after forward programming of the iPSC, resulting in a reversal of the one or more aging phenotypes in the cell. Also provided are artificially aged stem cells or somatic cells derived from iPSC by forward programming, and their use in methods of identifying genes or combinations of genes involved in aged phenotype reversal or non-aged phenotype maintenance in cells. Also provided are methods of identifying a gene or combination of genes involved in aging phenotype reversal or non-aging phenotype maintenance in a cell comprising introducing one or more aging-inducing factors into the cell or exposing the cell to one or more exogenous aging-inducing factors for a period of time, and measuring the aging phenotype of the cell. In particular, methods of identifying a gene or combination of genes involved in aging phenotype reversal or non-aging phenotype maintenance in a cell optionally include loss of function, inhibition, knockout, function acquisition, or combination screening. Also provided is a method of regenerating somatic cells comprising altering the expression and / or activity of one or more genes identified by the methods described herein.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof in the central nervous system or ex vivo. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a disease (e.g., a neurological disease), preventing a disease (e.g., neurological disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof.

The invention provides preparation, sorting and application of LGE / CGE organoid and GABAergic neurons, and belongs to the field of brain organoid differentiation and GABAergic neurons. The preparation method of the LGE / CGE type organ comprises the following steps: S1, performing embryoid formation and initial culture on the 0th-4th day; s2, performing nerve induction and matrigel embedding on the 5th-11th day; s3, culturing the brain organoid on the 12th day to the 19th day; s4, dynamically culturing and screening the brain organoid on the 20th-35th day; and S5, carrying out differentiation and collection on LCOs of the LGE / CGE type organs after the 35th day. According to the method, the LGE / CGE organs containing the high-purity GABA energy neurons are obtained through differentiation from the brain organs for the first time, the high-purity LGE type GABA energy neurons and the high-purity CGE type GABA energy neurons are obtained through a specific sorting method, and the method has the deep application potential in the fields of disease model construction, medicine research and development and the like.

The invention relates to a photoreceptor cell specific bidirectional promoter and application thereof. Specifically, the invention relates to a novel photoreceptor cell specific bidirectional promoter, an expression cassette containing the bidirectional promoter, a vector, a viral particle, a cell and a pharmaceutical composition, and application of the bidirectional promoter to treatment of eye diseases, such as retinal diseases.

To provide novel transduction enhancers and uses thereof.SOLUTION: The present invention relates to a method for transducing a target cell, the method comprising the step of contacting a target cell with a retroviral vector and a compound capable of enhancing transduction efficiency or a combination of such compounds, wherein the target cell is pre- and / or co-stimulated by pre- and / or co-incubation with a transduction enhancing compound or a combination of transduction enhancing compounds prior to and / or during contacting the target cell with the retroviral vector.SELECTED DRAWING: None

The invention relates to the technical field of biology, in particular to a composition for preparing a brain organ, the brain organ and application of the brain organ. The invention further discloses a construction method of the brain organ, and on the basis of the method, different stem cells such as ESCs and iPSCs can be utilized to stably construct the three-dimensional brain organ model capable of simulating the medulla oblongata trigeminal nerve. The invention further discloses an organoid assembly which has important application potential in the fields of research on development, functions and related diseases of brain nuclei, drug discovery and the like.

The invention provides universally acceptable “off-the-shelf” hypoimmunogenic pluripotent cells and differentiated cardiac, endothelial, neuronal, islet, or retinal pigment cells thereof. Such hypoimmune cells are used to treat patients in need thereof. The cells lack major immune antigens that trigger immune responses and are engineered to avoid phagocytic endocytosis.

The invention provides a stem cell exosome for overexpressing A beta degrading enzyme as well as a preparation method and application of the stem cell exosome. Specifically, the invention provides an application of the stem cell exosome overexpressing A beta degrading enzyme in preparation of drugs, and the drugs are used for at least one of the following: prevention, improvement or treatment of cognitive impairment related diseases; neuronal cell damage is improved; wherein the stem cells for overexpressing the A beta degrading enzyme are prepared through lentivirus transfection. According to the stem cell exosome overexpressing the A beta degrading enzyme, the content of the A beta degrading enzyme is obviously higher than that of the exosome prepared by a traditional method. Therefore, when the compound is prepared into a medicine for treating or preventing cognitive impairment related diseases, the medicine can be efficiently conveyed to the brain, and the concentration of the medicine in the brain is remarkably improved, so that the curative effect is enhanced, the dosage of the medicine can be reduced, the side effect is reduced, and the prognosis of brain diseases is effectively improved.

The invention discloses application of a CXCL14 combined immune checkpoint inhibitor in treatment of spinal glioma. The immune checkpoint inhibitor is selected from a PD-1 inhibitor or a combination of the PD-1 inhibitor and a CTLA4 inhibitor. In-vivo and in-vitro experiments prove that the CXCL14 combined with the PD-1 inhibitor, the CXCL14 combined with the PD-1 inhibitor and the CTLA4 inhibitor can be used for remarkably inhibiting the growth of mutant spinal glioma and have a remarkable synergistic effect. The invention provides a new strategy for treatment of spinal glioma, and is widely applied clinically.

The invention provides a marker of spinal cord functional neural precursor cells, a detection method and a sorting method, and belongs to the technical field of biological medicine. The invention provides application of a marker detection reagent in preparation of a kit for detecting spinal cord functional neural precursor cells. The invention further provides a sorting-based method for separating the SFNPCs cells, and the cells are sorted through the Marker of the specific SFNPCs, so that the cell purity of the SFNPCs is remarkably improved, the difference between batches is reduced, and a high-purity and homogeneous SFNPCs cell population is obtained. The survival rate of the SFNPCs cells separated and subcultured to the P9 generation by the method disclosed by the invention is more than 85%, and the SFNPCs cells have a good treatment effect on a spinal cord injury model.